Mankind Pharma to Leverage OpenAI’s GPT-5 to scale AI-enabled Pharma Transformation

by leveraging its latest GPT-5, Mankind aims to unlock efficiency and introduce innovative solutions across its entire value chain, including drug discovery, enhance clinical research, optimize manufacturing processes, and strengthen patient engagement through AI-powered insights

Leading pharma giants, Mankind Pharma, has announced its collaboration with OpenAI to integrate advanced artificial intelligence capabilities across its pharmaceutical value chain.

Reportedly, the pharmaceutical company seeks to leverage OpenAI’s latest models, including GPT-5 to innovate in pharmaceutical arenas.

Further, ManKind seeks to streamline operational efficiency and enhance innovation with the goal of delivering value to doctors, patients, and the entire healthcare ecosystem.

Speaking of the collaboration, Arjun Juneja, Chief Operating Officer at Mankind Pharma, said, “At Mankind Pharma, we see working with OpenAI as a pivotal step in building the pharma organization of the future. By integrating advanced AI into our core operations, we’re enabling our teams to move faster, work smarter, and unlock insights that drive real-world impact, whether it’s in field force effectiveness, supply chain agility, or R&D acceleration. This is not just about automation; it’s about creating a more responsive, intelligent, and future-ready enterprise. We’re excited to lead this shift in Indian pharma and set new benchmarks for how technology can drive both operational excellence and long-term value creation.”

The Partnership Agenda

As part of this initiative, Mankind will integrate OpenAI across multiple operational functions, including field force enablement, digital marketing, research and development (R&D), manufacturing, and medical affairs.

The integration of ChatGPT into its operation, especially by leveraging its latest GPT-5, Mankind aims to unlock efficiency and introduce innovative solutions across its entire value chain, including drug discovery, enhance clinical research, optimize manufacturing processes, and strengthen patient engagement through AI-powered insights.

Moreover, it is expected to strengthen clinical intelligence by streamlining literature reviews, enhancing manufacturing quality with AI-driven anomaly detection, and raising operational standards.

Recently, Mankind has rolled out custom GPT tools across its workforce, improving messaging, demand planning, procurement, and commercial operations, giving leadership better visibility and freeing them to focus on growth.

Sharing thoughts, Oliver Jay, Managing Director, International at OpenAI, said, “Mankind Pharma’s company-wide adoption of ChatGPT Enterprise shows the practical role AI can play in regulated industries such as pharmaceuticals. By integrating advanced AI into areas like research, operations, and medical communications, Mankind is taking meaningful steps to improve efficiency and support innovation. We look forward to working with them in exploring how AI can be applied responsibly and safely to deliver value within their organization and across the healthcare ecosystem.”

Stay tuned for more such updates on Digital Health News